Drug General Information
Drug ID
D0SP3D
Former ID
DAP000852
Drug Name
Dihydroergotoxine
Synonyms
Agit; Angionorm; Dehydroergotamine; Dergotamine; Diergo; Dihidroergotamina; Dihydergot; Dihydroergotamine; Dihydroergotaminum; Dihydroergotoxin; Diidroergotamina; Dirgotarl; Endophleban; Ergomimet; Ergont; Ergotonin; Ikaran; Migranal; Morena; Neomigran; Orstanorm; Seglor; Tonopres; Verladyn; DET MS; Dihydroergotamine methanesulfonate; Diidroergotamina [DCIT]; Ergoloid dihydroergotoxine; Co-Dergocrine; DHE-45; Dihidroergotamina [INN-Spanish]; Dihydroergotamine (INN); Dihydroergotaminum [INN-Latin]; Ergoloid Mesylates (dihydroergotoxine); Ergot Alkaloids, Hydrogenated; Neomigran (TN); Ergotamine, dihydro, methanesulfonate (salt); (10alphaH)-5'alpha-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman; (5'alpha)-12'-Hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione; (5'alpha)-5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxoergotaman; 5'-Benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman; 9,10-Dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione; 9,10-Dihydroergotamine; 9,10-dihydro-ergotamine
Drug Type
Small molecular drug
Indication Alzheimer disease [ICD9: 331; ICD10:G30] Approved [534844]
Therapeutic Class
Vasodilator Agents
Structure
Download
2D MOL

3D MOL

Formula
C34H41N5O8S
Canonical SMILES
CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5C<br />C6C(CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O
InChI
1S/C33H37N5O5.CH4O3S/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32;1-5(2,3)4/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39);1H3,(H,2,3,4)
InChIKey
ADYPXRFPBQGGAH-UHFFFAOYSA-N
CAS Number
CAS 11032-41-0
PubChem Compound ID
PubChem Substance ID
SuperDrug ATC ID
C04AE01; N02CA01
Target and Pathway
Target(s) Glutamate receptor AMPA subtype Target Info Agonist [534844]
D(2) dopamine receptor Target Info Agonist [534844]
KEGG Pathway Rap1 signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholism
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathway
Reactome Dopamine receptors
G alpha (i) signalling events
WikiPathways Hypothetical Network for Drug Addiction
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Genes and (Common) Pathways Underlying Drug Addiction
GPCR ligand binding
GPCR downstream signaling
Nicotine Activity on Dopaminergic Neurons
References
Ref 534844Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97.
Ref 534844Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.